INMB News and Press, INmune Bio Inc. From 09/07/22

Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that RJ Tesi, M.D., Chief Executive Officer will present ...

Image source: The Motley Fool. INmune Bio, Inc. (NASDAQ: INMB) Q2 2022 Earnings Call Aug 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript

INmune Bio, Inc. (INMB) Q2 2022 Earnings Conference Call August 03, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Co-Founder and Chief Executive Officer Mark Lowdell – Co-Founder and Chief ...

INmune Bio press release ( NASDAQ: INMB ): Q2 GAAP EPS of -$0.38. Revenue $16K. For further details see: INmune Bio GAAP EPS of -$0.38

BOCA RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its fin...

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a...

Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D. BTIG Biotechnology Conference – Fireside Conv...

INmune Bio and Alector are seeking to treat Alzheimer's disease by decreasing neuroinflammation while maintaining a healthy immune response. However, neither company's drug candidate appears to address the oxidative stress that precedes neuroinflammation. Anti-inflammatory drug ca...

INmune Bio (NASDAQ:INMB) said it received a U.S. patent covering a use of its therapy XPro, which is being explored to treat central nervous system (CNS) disorders. The U.S. Patent No. 11,365,229 is titled “Methods of treating neurological diseases,” is directed toward use of Do...

Boca Raton, Florida, June 22, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces the issuance ...